Roche Holding stock reports 6.00 percent first half sales growth
Published on 09/30/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding (ISIN CH0012032048) generated CHF 30.36 billion in first-half 2026 sales, up 6.00 percent at constant exchange rates. The result keeps the pipeline at the center of the investment case, with RBC retaining an Outperform rating and a CHF 400.00 price target after new kidney-disease data.
Pipeline data support the case
According to finanzen.net on September 23, 2026, RBC left its Outperform view and CHF 400.00 target unchanged after Phase 3 data for Sefaxersen in IgA nephropathy. The analyst described the results as a step toward reducing risk around the program and as support for Roche's wider pipeline assessment.
The comparison with the first half of 2025 is meaningful: Roche's sales growth reached 6.00 percent at constant exchange rates, while core diluted earnings per share rose 9.00 percent to CHF 10.85, according to Muffett Investments. The figures point to earnings growth outpacing reported sales growth during the period.
October brings the next checkpoint
Roche's investor-relations update states that third-quarter 2026 sales will be published before the Swiss exchange opens on October 22, 2026, with a presentation scheduled for 2:00 p.m. CEST. The date gives investors a defined checkpoint for judging whether the first-half growth profile is carrying into the second half.
Roche combines pharmaceuticals and diagnostics, so the next sales release will also show whether both divisions are sustaining the group's expansion. The company reported that 39 million patients received Roche medicines in 2025, while 31 billion diagnostic tests were delivered to customers worldwide, according to Roche.
SIX quote remains below yearly high
On September 30, 2026, Roche was trading at CHF 363.00 on SIX at 11:42 a.m. CEST. Its 52-week range was CHF 270.80 to CHF 383.00, placing the quote CHF 20.00 below the high and CHF 92.20 above the low. Market capitalization stood at CHF 284.6 billion on the same date.
Roche Holding stock facts
- Company: Roche Holding AG
- ISIN: CH0012032048
- Ticker: ROG
- Primary exchange: SIX Swiss Exchange
- Market capitalization: CHF 284.6 billion (as of September 30, 2026)
- 52-week range: CHF 270.80-383.00 (as of September 30, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: SMI
- Next earnings date: October 22, 2026
